<DOC>
	<DOC>NCT01239992</DOC>
	<brief_summary>The study is designed to evaluate the effect of Niacin/Laropiprant on postprandial lipoprotein metabolism, postprandial glucose metabolism, postprandial monocyte function, and postprandial biomarkers of endothelial dysfunction and inflammation.</brief_summary>
	<brief_title>Effect of Niacin/Laropiprant on Postprandial Lipoprotein Metabolism in Patients With Dyslipoproteinemia</brief_title>
	<detailed_description />
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Hyperlipoproteinemias</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Male subjects or postmenopausal female subjects aged between 1970 years High risk patients (PROCAM risk ≥20%) on a stable statintherapy, but at least simvastatin 20 mg/d HDLcholesterol ≤50 mg/dl and /or triglycerides 150400 mg/dl and/or LDLcholesterol 70 150 mg/dl Lipoprotein (a) &lt; 30 mg/dl Patients may have normal glucose metabolism (normal HOMA), be insulin resistant (abnormal HOMA), have impaired fasting glucose or impaired glucose tolerance but not diabetes mellitus. Without niacin therapy for at least 6 months Dosage of any concomitant medication has been stable for at least 3 weeks If female, postmenopausal (absence of menstruation for at least 12 months or absence of menstruation &gt; 6 months with FSH &gt; 40 ng/ml respectively oestrogen &lt; 20 pg/ml) Subjects with additional causes for hyperlipoproteinemia Diabetes mellitus or antidiabetic medication Subject has history of cardiovascular ischemia in previous 3 months or acute myocardial infarction or unstable angina History of psychiatric disorder or cognitive impairment that would interfere with participation in the study History of alcoholism Contraindication against niacin and/or laropiprant Subject has participated in an investigational study within 30 days prior to study initiation Fasting triglycerides &gt;400 mg/dl Lifethreatening disease (e.g. cancer) Renal insufficiency (GFR ≤ 30 ml/min ) Major hepatic impairment Known allergic reaction/intolerance against niacin and/or laropiprant Active peptic ulcer disease</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>